What is FluidForm?
FluidForm is a pioneering entity in the field of regenerative medicine, recognized as a global leader in the creation of functional human tissue. Leveraging its proprietary FRESH 3D printing technology, the company has established the most advanced biofabrication platform currently available, as validated by publications in prestigious scientific journals like Science. FluidForm's robust pipeline is dedicated to addressing critical unmet needs in human health through the development of bioprosthetic implantable medical devices and next-generation tissue models for drug efficacy and cardiotoxicity testing. The ultimate vision is to achieve tissue and organ replacement, positioning FluidForm at the forefront of medical innovation.
How much funding has FluidForm raised?
FluidForm has raised a total of $310K across 2 funding rounds:
Debt
$150K
Debt
$160K
Debt (2020): $150K with participation from PPP
Debt (2021): $160K led by PPP
What's next for FluidForm?
With its large-scale late-stage funding, FluidForm is poised for significant expansion and the acceleration of its development programs. The capital infusion is expected to fuel the advancement of its bioprosthetic implantable medical devices and the refinement of its complex tissue models for pharmaceutical research. The company's strategic focus on tissue and organ replacement suggests a future where FluidForm could revolutionize treatment paradigms for a wide range of medical conditions, marking a new era in patient care and therapeutic solutions.
See full FluidForm company page
